Henry L. Han

Henry L. Han

Auto-generated profile, based on publicly available information

Henry L. Han

Erasmus MC University Medical Centre, Rotterdam – Sophia Children’s Hospital – Department of Dermatology – Center of Pediatric Dermatology/Center of Rare Skin Diseases , Rotterdam

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2023 in Contact Dermatitis
Verified
Journal Article
Open access
EKEsmé Kamphuis
Esmé Kamphuis
LLLaura Loman
Laura Loman
HHHenry L. Han
Henry L. Han
GRGeertruida L. E. Romeijn
Geertruida L. E. Romeijn
KPKlaziena Politiek
Klaziena Politiek
MSMarie L.A. Schuttelaar
Marie L.A. Schuttelaar
Background: Real‐world data on the effectiveness of upadacitinib on atopic dermatitis (AD), hand eczema (HE) and HE in the context of AD are limited.Objectives: To evaluate the effectiveness and safety of upadacitinib on AD and on HE in patients with AD.Methods: This prospective observational cohort study includes clinical outcomes: Eczema Area and Severity Index (EASI), Investigator's Global Assessment (IGA), Hand Eczema Severity Index (HECSI), Photographic guide; and PROMs: average pruritus and pain Numeric Rating Scale (NRS) score of the past week, Patient‐Oriented Eczema Measure (POEM), Patient‐Oriented Eczema, Dermatology Life Quality Index (DLQI), Atopic Dermatitis Control Tool (ADCT), Patient Global Assessment of Disease (PGAD), Quality Of Life Hand Eczema Questionnaire (QOLHEQ) at baseline, Week 4, and Week 16 of upadacitinib‐treated patients. Adverse events were monitored during each visit.Results: Thirty‐eight patients were included, of which 32 patients had HE. At Week 16, EASI‐75 was achieved by 50.0%. Absolute cutoff score NRS‐pruritus ≤4 was reached by 62.5%, POEM ≤7 by 37.5%, DLQI ≤5 by 59.4%, ADCT <7 by 68.8%, and PGAD rating of at least ‘good’ by 53.1%. HECSI‐75 was achieved by 59.3% and (almost) clear on the Photographic guide by 74.1%. The minimally important change in QOLHEQ was achieved by 57.9%. Sub‐analysis in patients with concomitant irritant contact dermatitis showed no differences. Safety analysis showed no new findings compared to clinical trials.Conclusions: Upadacitinib can be an effective treatment for patients with AD and concomitant HE in daily practice. Future studies should focus on the effectiveness of upadacitinib on chronic HE, especially on the different etiological subtypes of HE, including HE in non‐atopic individuals.

16 June 2026 in British Journal of Dermatology
Verified
Journal Article
Closed access
ECEdwin Cuperus
Edwin Cuperus
SPSuzanne G M A Pasmans
Suzanne G M A Pasmans
HHHenry L Han
Henry L Han
AAAdam S Arterbery
Adam S Arterbery
DDDaniel Danis
Daniel Danis
MGMariëlle E van Gijn
Mariëlle E van Gijn
This study brings the Human Phenotype Ontology into dermatology, refining and expanding its use for Netherton syndrome (SPINK5-sEDD). The updated terms significantly boost diagnostic performance and enhance clinical phenotyping. It highlights the promise of ontology-based tools for rare skin diseases.